CGTX FY2025 EPS Forecast Cut by Brookline Capital Management

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Cognition Therapeutics in a research note issued on Monday, November 10th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.35) per share for the year, down from their prior forecast of ($0.34). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01.

Several other equities research analysts also recently commented on the stock. Wall Street Zen raised shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Cognition Therapeutics in a research report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of Cognition Therapeutics in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $2.83.

Cognition Therapeutics Price Performance

Shares of NASDAQ:CGTX opened at $1.75 on Wednesday. The company has a market capitalization of $154.47 million, a price-to-earnings ratio of -3.65 and a beta of 1.23. The firm’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $1.10. Cognition Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $3.83.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently modified their holdings of CGTX. DAVENPORT & Co LLC bought a new stake in Cognition Therapeutics in the 3rd quarter valued at approximately $3,631,000. Vanguard Group Inc. raised its holdings in shares of Cognition Therapeutics by 105.6% in the third quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock valued at $3,620,000 after purchasing an additional 1,377,263 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after purchasing an additional 897,353 shares in the last quarter. CM Management LLC lifted its position in shares of Cognition Therapeutics by 100.0% in the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $168,000 after purchasing an additional 200,000 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Cognition Therapeutics during the third quarter worth $265,000. 43.35% of the stock is currently owned by institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.